American Trust Sells 1,069 Shares of Hologic, Inc. (NASDAQ:HOLX)

American Trust decreased its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 19.4% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm owned 4,434 shares of the medical equipment provider’s stock after selling 1,069 shares during the period. American Trust’s holdings in Hologic were worth $358,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in HOLX. GPS Wealth Strategies Group LLC purchased a new position in Hologic in the 1st quarter worth approximately $28,000. Sageworth Trust Co purchased a new position in Hologic in the first quarter worth $34,000. Salem Investment Counselors Inc. increased its stake in Hologic by 163.9% in the second quarter. Salem Investment Counselors Inc. now owns 549 shares of the medical equipment provider’s stock valued at $38,000 after acquiring an additional 341 shares during the last quarter. Clear Street Markets LLC raised its position in Hologic by 91.3% during the first quarter. Clear Street Markets LLC now owns 484 shares of the medical equipment provider’s stock valued at $39,000 after purchasing an additional 231 shares in the last quarter. Finally, Whittier Trust Co. raised its position in Hologic by 55.5% during the first quarter. Whittier Trust Co. now owns 591 shares of the medical equipment provider’s stock valued at $48,000 after purchasing an additional 211 shares in the last quarter. 92.64% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on HOLX shares. Raymond James reduced their price objective on Hologic from $100.00 to $95.00 and set an “outperform” rating on the stock in a research report on Tuesday, August 1st. Bank of America decreased their price target on shares of Hologic from $94.00 to $86.00 and set a “neutral” rating on the stock in a research note on Tuesday, August 1st. Royal Bank of Canada cut their price objective on shares of Hologic from $87.00 to $85.00 and set a “sector perform” rating for the company in a research note on Tuesday, August 1st. StockNews.com assumed coverage on shares of Hologic in a research report on Friday, August 18th. They issued a “buy” rating on the stock. Finally, Needham & Company LLC reissued a “buy” rating and issued a $95.00 price target on shares of Hologic in a research note on Tuesday, August 1st. Six equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $88.92.

Hologic Stock Down 0.7 %

Shares of NASDAQ:HOLX opened at $71.81 on Friday. Hologic, Inc. has a 1 year low of $59.78 and a 1 year high of $87.88. The company has a debt-to-equity ratio of 0.54, a current ratio of 4.42 and a quick ratio of 3.73. The stock’s 50-day moving average is $76.35 and its 200 day moving average is $79.30. The company has a market cap of $17.59 billion, a PE ratio of 37.21 and a beta of 1.01.

Hologic (NASDAQ:HOLX) last posted its earnings results on Monday, July 31st. The medical equipment provider reported $0.93 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.89 by $0.04. Hologic had a return on equity of 19.02% and a net margin of 11.99%. The firm had revenue of $984.40 million for the quarter, compared to analysts’ expectations of $960.22 million. During the same period in the previous year, the firm earned $0.95 earnings per share. The business’s revenue was down 1.8% compared to the same quarter last year. Sell-side analysts anticipate that Hologic, Inc. will post 3.92 EPS for the current year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health.